The Structural Shift in Foot Surgery: Forma Medical's New MIPA Patent

CAMP HILL, PA – October 21, 2026 – The human foot is an intricate matrix of structural engineering, a highly specialized suspension system comprising 26 bones and 33 joints designed to bear the entire weight of the human body. When this localized infrastructure begins to fray—whether through the degenerative wear of arthritis or progressive mechanical deformity—orthopedic surgeons are tasked with restoring its foundational stability. For decades, the gold standard for this restoration has been arthrodesis, or joint fusion. Yet, the procedure has historically forced a harsh compromise between mechanical stability and biological preservation. On October 6, 2026, Camp Hill-based Forma Medical Inc. secured a patent that promises to eliminate this compromise, signaling a structural shift in how we approach extremity reconstruction.

The U.S. Patent and Trademark Office issued U.S. Patent No. 12,751,749, titled "System for Joint Fixation of Extremity Bone and Related Methods," to Forma Medical. The patent formalizes the intellectual property surrounding a surgical method the company calls minimally invasive plate arthrodesis, or MIPA. By utilizing small incisions to introduce and secure a fixation plate across a damaged joint, MIPA challenges the long-held orthodoxies of foot and ankle surgery. It is a development that warrants a forensic look, not just for its clinical implications, but for how it illustrates the intersection of biomechanical innovation and strategic market positioning.

Borrowing from the Trauma Playbook

To understand the significance of MIPA, one must look at the historical constraints of joint fusion. Traditionally, surgeons aiming to permanently join two bones at the big toe, midfoot, or hindfoot have relied on open surgical exposure. This requires a large incision, stripping away soft tissue and disrupting the localized blood supply in order to implant a stabilizing metal plate. The alternative approach, aimed at minimizing tissue damage, has been percutaneous screw fixation—driving screws through tiny keyhole incisions. However, screws alone often lack the multi-planar rigidity of a plate, occasionally compromising the structural integrity of the fusion in heavy weight-bearing joints.

Forma Medical’s MIPA technique resolves this tension by looking backward to a revolution that occurred in fracture care. In the 1990s, orthopedic trauma surgeons began adopting minimally invasive plate osteosynthesis (MIPO). Instead of flaying open a shattered leg or arm, they learned to slide fracture plates beneath the skin and muscle, securing them through minimal incisions. This preserved the biological environment necessary for rapid bone healing while delivering robust mechanical support.

MIPA applies this exact philosophy to elective joint fusion. "In urgent fracture care, we have evolved to less invasive surgical approaches for internal fixation, with less anatomic distortion and soft tissue dissection," explained Dr. Jesse F. Doty, a fellowship-trained orthopedic foot and ankle surgeon at Integrity Orthopedics, Professor of Orthopaedic Surgery at the University of Tennessee, and co-inventor of the patented technology. "Elective fusion has been slower to progress to an established equivalent until now. MIPA offers a defined, repeatable way to deliver more robust plate fixation through smaller incisions, providing the same benefits we've seen from minimally invasive surgery in other anatomic areas, but without compromised stability."

The Anatomy of an Intellectual Property Moat

From a market perspective, the issuance of Patent No. 12,751,749 is a masterclass in intellectual property strategy. In the highly competitive orthopedic device sector, dominated by behemoths like Stryker, Arthrex, and DePuy Synthes, smaller innovators often struggle to protect their market share. A novel screw thread or a slightly modified plate design can easily be engineered around by competitors equipped with massive research and development budgets.

Forma Medical, however, has focused its primary claims on the method rather than just the widget. The patent covers the surgical methodology of introducing and securing a plate across extremity joints via small incisions. By patenting the procedure itself—the specific sequence of accessing the joint, preparing the bone surfaces, sliding the plate, and securing the hardware—Forma Medical has constructed a formidable structural moat around its business model.

"When a company secures a broad method patent in the orthopedic space, they aren't just protecting a piece of metal; they are protecting a surgical philosophy," noted an independent medical technology analyst familiar with the foot and ankle market. "It forces competitors to either license the approach, attempt to invalidate the patent, or stick to inferior legacy techniques. It is a highly strategic maneuver that elevates the company's valuation and long-term market leverage."

This strategic positioning is already yielding tangible clinical adoption. Forma’s flagship OptimalMTP system, designed specifically for first metatarsophalangeal (big toe) joint fusion using the MIPA technique, received FDA 510(k) clearance in 2024. The company reports that the system has been utilized in more than 1,000 procedures to date. Crucially, the new patent claims extend well beyond the big toe, covering other critical joints of the foot where surgeons traditionally reach for a plate, such as the tarsometatarsal and subtalar joints.

Ending the Surgical Compromise for Patients

At the intersection of medical policy and public health, the ultimate metric of any technological advancement is its direct impact on the citizen. For patients suffering from debilitating foot arthritis or severe mechanical deformities, the prospect of fusion surgery has always been a daunting calculus. The traditional open approach often means weeks of severe swelling, a higher risk of wound healing complications, and a prolonged, painful rehabilitation period. The large incisions required for open plating are particularly problematic in the foot, where the soft tissue envelope is notoriously thin and vulnerable to postoperative infection.

By transitioning to a minimally invasive approach, MIPA fundamentally alters this patient experience. Smaller incisions translate directly to reduced soft tissue trauma, which in turn minimizes postoperative pain and accelerates the body's natural healing cascade. Patients are no longer forced to choose between the reliable stability of a plate and the easier recovery of a minimally invasive procedure.

"The fixation surgeons trust, through the small incisions patients ask for. That is what surgeons told us they needed, and MIPA is designed to deliver both," stated Andrew C. Davison, CEO of Forma Medical. This dual mandate—satisfying the surgeon's biomechanical requirements while meeting the patient's desire for a less traumatic physical experience—is the holy grail of modern orthopedic design.

The Road Ahead for Extremity Orthopedics

As we track the structural integrity of our modern healthcare system, the shift toward minimally invasive techniques is not merely a passing trend; it is a systemic imperative. An aging demographic, coupled with rising rates of obesity and diabetes, guarantees a surging demand for foot and ankle reconstruction over the coming decades. Healthcare systems, heavily burdened by soaring operational costs, are increasingly prioritizing surgical methods that reduce hospital stays, lower complication rates, and return citizens to the workforce faster.

However, the widespread adoption of MIPA will not be without its hurdles. The technique demands a high degree of technical proficiency and specialized spatial awareness. "The learning curve is always the hidden variable in minimally invasive plating," an academic foot and ankle surgeon remarked regarding the broader industry shift. "You are relying heavily on intraoperative fluoroscopy to guide your hands because you cannot fully visualize the bone. If the clinical data holds up, the benefits to soft tissue preservation are undeniable, but it requires a definitive shift in surgical muscle memory and training protocols."

The orthopedic community is inherently driven by empirical evidence, and the true test of Forma Medical's patented method will lie in peer-reviewed clinical outcomes. Dr. Doty has utilized MIPA for MTP joint fusions in his own practice for years, noting highly encouraging patient feedback, and he plans to submit his long-term clinical outcomes for publication later this year. As those results enter the public square, they will likely determine whether minimally invasive plate arthrodesis becomes the new standard of care across all extremity joints, or remains a specialized technique. For now, Forma Medical has successfully patented a bridge between the structural demands of the human skeleton and the evolving expectations of the modern surgical patient.